Radient Technologies Inc. appointed Mr. Christian Aigner to the position of Managing Director, Germany. Reporting to its Chief Operating Officer, Mr. Aigner will be responsible for the development and management of its German processing facility, and will also provide valuable direction to the overall design and execution of each of its global manufacturing projects. Mr. Aigner brings to the company more than 30 years' experience in the design, construction, and optimization of pharmaceutical and manufacturing facilities, including 10 years as Operational Excellence Manager with Sandoz GmbH in Kundl, Austria. He has successfully completed more than 30 projects in 20 countries, including the design, build-out and management of Teva Biotech GmbH's new biotech facility in Ulm, Germany; Kathrein Mobilecom's manufacturing facility in Tlaxcala, Mexico; and YTONG AAC's semi-automated manufacturing plants in the USA, Russia, Hong Kong, and South Korea. Mr. Aigner holds an MBA (Post Graduate Management) from WU Executive University Vienna, and received his designation as a Mechanical Engineering and Production Technology Engineer from the Federal Ministry of Economic Affairs in Vienna, Austria.

The company announced that the development of a new Manufacturing Facility of over 100,000 square feet dedicated to cannabinoid extraction and product development has begun on the land adjacent to the company's existing facility in Edmonton, Alberta. The New Facility, expected to be complete in 2020, will allow Radient additional extraction capacity and cannabinoid ingredient development capability in order to serve its partners, including Aurora Cannabis Inc., which currently has approximately 570,000 kgs of funded cannabis cultivation capacity. New European Processing Facility: Radient has advanced its plans to construct a large-scale cannabis processing facility in Germany, comparable in capacity to the New Facility being built in Edmonton. Designs for the European facility are focused in the near-term on the consistent, industrial-scale delivery of CBD derivatives and formulations, manufactured in the EU GMP environment. Site selection in Germany has been made, with site preparation nearing completion and the construction permitting having begun.